AJANTPHARM.NS Cash Flow
Ajanta Pharmaceuticals Ltd.
Profit & Loss Balance Sheet Cash Flow
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:33
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹7.92 Bn | ₹7.85 Bn | ₹11.57 Bn | ₹5.29 Bn | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹-5.60 Bn | ₹0.65 Bn | ₹-3.77 Bn | ₹-4.29 Bn | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹-1.08 Bn | ₹-10.51 Bn | ₹-7.33 Bn | ₹-1.68 Bn | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹-0.01 Bn | ₹0.00 Bn | ₹-0.02 Bn | ₹-0.04 Bn | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹1.23 Bn | ₹-2.00 Bn | ₹0.46 Bn | ₹-0.72 Bn | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹2.06 Bn | ₹3.30 Bn | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
Every figure above is the exact value of the named XBRL element from AJANTPHARM.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).